G35.C2

Clinical Causes: The exact cause of MS, including non-active secondary progressive MS, remains unknown. Genetic predispositions may play a role in susceptibility. Environmental factors such as Vitamin D deficiency, smoking, and viral infections have been linked to disease development. The transition from relapsing-remitting MS to secondary progressive MS appears to involve cumulative nerve damage over time. No current evidence suggests active inflammatory processes are ongoing in the non-active phase.

Key Symptoms: Gradual worsening of neurological function such as weakness, numbness, or difficulty with coordination. Increasing problems with walking or balance. Mild to moderate spasticity or muscle stiffness. Persistent fatigue that worsens over time. Bladder or bowel dysfunction.

Diagnosis Path: Diagnosis involves a comprehensive clinical assessment, including neurological examinations and medical history review. Imaging studies like MRI scans are used to observe brain and spinal cord changes. In cases of non-active secondary progressive MS, MRI typically shows no new or enhancing lesions, indicating a lack of active inflammation. Additional tests may include evoked potentials and cerebrospinal fluid analysis to exclude other causes and confirm disease progression. It’s important that healthcare providers distinguish this stage from active MS to tailor management strategies accordingly.

Treatment Protocols: Symptomatic management such as muscle relaxants for spasticity, medications for fatigue, and bladder or bowel issues. Physical therapy to maintain mobility and strength. Occupational therapy to assist with daily activities. Monitoring disease progression with regular follow-ups. Emerging therapies and clinical trials aiming to modify disease progression are continually being evaluated, but their applicability depends on individual circumstances. Corticosteroids are not typically used in non-active phases unless there is evidence of new inflammatory activity. Disease-modifying therapies are often discontinued if there’s no active inflammation, but decisions are individualized.